WuXi AppTec (HKG:2359) has completed the sale of its WuXi Clinical Development Services (Shanghai) and WuXi MedKey Med-Tech Development (Shanghai) units to asset manager Hillhouse Investment Management, according to a Hong Kong bourse filing Monday.
Shares of the drug research company fell over 1% in midday trade Tuesday.
The firm said it received the first installment payment of the consideration in the amount of 1.54 billion yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.